Recent treatment advances and novel therapies in pancreas cancer: a review.

ABSTRACT:

Purpose

Over the last couple of years, we have witnessed the availability of a wide variety of different therapeutic agents and the identification of effective combinations of existing ones that have transformed the way we approach and treat pancreatic cancer. Proof of this are the recent validations that combinations of conventional chemotherapy drugs, the FOLFIRINOX regimen and gemcitabine plus nab-paclitaxel, significantly improves clinical outcomes in patients with metastatic disease. However, deeper and more sophisticated understanding of the biology of this cancer as well as the ability to develop better and perhaps more precise drugs predict that the landscape may be changing even more.

Methodology and results

In this review, we will summarize the most recent treatmen

SUBMITTER: Valsecchi ME 

PROVIDER: S-EPMC4024386 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature